Liver Cancer – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Liver Cancer – Pipeline Review, H2 2016’, provides an overview of the Liver Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Liver Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Liver Cancer

The report reviews pipeline therapeutics for Liver Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Liver Cancer therapeutics and enlists all their major and minor projects

The report assesses Liver Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Liver Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Liver Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Liver Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

AB Science SA

Acceleron Pharma Inc

ACROVIS Pharma AG

Adaptimmune Therapeutics Plc

Aduro BioTech Inc

Advenchen Laboratories LLC

Alfact Innovation

Alissa Pharma

Alnylam Pharmaceuticals Inc

American Gene Technologies International Inc

Amgen Inc

AndroScience Corp

APAvadis Biotechnologies Srl

ArQule Inc

Array BioPharma Inc

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

AVEO Pharmaceuticals Inc

Bayer AG

BeiGene Ltd

Beijing Kawin Technology Share-Holding Co Ltd

Betta Pharmaceuticals Co Ltd

Bio-Cancer Treatment International Ltd

BioCancell Ltd

Biogazelle NV

Biomics Biotechnologies Co Ltd

Bioneer Corp

BioStar Pharmaceuticals Inc

BLR Bio LLC

Blueprint Medicines Corp

Boehringer Ingelheim GmbH

Boryung Pharmaceutical Co Ltd

Boston Biomedical Inc

Bristol-Myers Squibb Company

Can-Fite BioPharma Ltd

CASI Pharmaceuticals Inc

CBT Pharmaceuticals Inc

CCRP Therapeutics GmbH

Celgene Corp

Celldex Therapeutics Inc

Celprogen Inc

Celsion Corp

China Medical System Holdings Ltd

Chiome Bioscience Inc

Chipscreen Biosciences Ltd

Chroma Therapeutics Ltd

Chugai Pharmaceutical Co Ltd

CohBar Inc

CZ BioMed Corp

Daiichi Sankyo Company Ltd

Delcath Systems Inc

Dicerna Pharmaceuticals Inc

Double Bond Pharmaceutical International AB

Eisai Co Ltd

Eli Lilly and Company

Endocyte Inc

Epeius Biotechnologies Corp

eTheRNA Immunotherapies NV

Eureka Therapeutics Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Faron Pharmaceuticals Oy

Formosa Laboratories Inc

Galaxy Biotech LLC

Genelux Corp

Genoscience Pharma

Genosco Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

Golden Biotechnology Corp

Green Cross Cell Corp

Green Cross Corp

H3 Biomedicine Inc

HanAll Biopharma Co Ltd

HEC Pharm Co Ltd

HitGen LTD

Horizon Pharma Plc

Immune Therapeutics Inc

Immunicum AB

Immunitor Inc

Immunomedics Inc

Immunophotonics Inc

Immunovative Therapies Ltd

IMPACT Therapeutics Inc

In-Cell-Art SAS

Incanthera Ltd

Inovio Pharmaceuticals Inc

Inspyr Therapeutics Inc

InteRNA Technologies BV

Intezyne Technologies Inc

Jasco Pharmaceuticals LLC

Jenrin Discovery Inc

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

JW Pharmaceutical Corp

KAHR medical Ltd

Karcinolys SAS

Keystone Nano Inc

Kite Pharma Inc

Komipharm International Co Ltd

Kowa Company Ltd

Les Laboratoires Servier SAS

Lidds AB

Ligand Pharmaceuticals Inc

Lixte Biotechnology Holdings Inc

Lytix Biopharma AS

MaxCyte Inc

MedImmune LLC

Medivation Inc

Medivir AB

Merck & Co Inc

Merck KGaA

Merrimack Pharmaceuticals Inc

Midatech Pharma Plc

Millennium Pharmaceuticals Inc

Mina Therapeutics Ltd

Molecular Partners AG

MultiCell Technologies Inc

NormOxys Inc

Northwest Biotherapeutics Inc

Novartis AG

NovaTarg Therapeutics Inc

Nymox Pharmaceutical Corp

Omeros Corp

Omnitura Therapeutics Inc

Oncolys BioPharma Inc

OncoMed Pharmaceuticals Inc

OncoTherapy Science Inc

Oneness Biotech Co Ltd

Ono Pharmaceutical Co Ltd

Onxeo SA

OPKO Health Inc

Oribase Pharma

OSE Immunotherapeutics

Otsuka Holdings Co Ltd

Panacea Pharmaceuticals Inc

Peptinov SAS

PepVax Inc

Peregrine Pharmaceuticals Inc

Pfizer Inc

Pharma Mar SA

PharmAbcine Inc

PharmaEssentia Corp

Phosplatin Therapeutics LLC

ProMetic Life Sciences Inc

Provecs Medical GmbH

Provectus Biopharmaceuticals Inc

RedHill Biopharma Ltd

Regen BioPharma Inc

Regulus Therapeutics Inc

Rigontec GmbH

Samumed LLC

Saronic Biotechnology Inc

Savoy Pharmaceuticals Inc

Shenogen Pharma Group Ltd

Shenzen SiBiono GeneTech Co Ltd

Silence Therapeutics Plc

Sillajen Biotherapeutics

Simcere Pharmaceutical Group

Somantix BV

Sorrento Therapeutics Inc

Synovo GmbH

TaiRx Inc

Taiwan Liposome Company Ltd

Tara Immuno-Oncology Therapeutics LLC

Targetome SA

TC BioPharm Ltd

Tessa Therapeutics Pte Ltd

Therapure Biopharma Inc

Theravectys SA

Threshold Pharmaceuticals Inc

Tiziana Life Sciences Plc

TRACON Pharmaceuticals Inc

Transgene Biotek Ltd

Tumorend LLC

UbiVac LLC

VasGene Therapeutics Inc

Vaxon Biotech

Vect-Horus SAS

Verlyx Pharma Inc

VG Life Sciences Inc

Vicus Therapeutics LLC

Virttu Biologics Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 10

Liver Cancer Overview 11

Therapeutics Development 12

Liver Cancer - Therapeutics under Development by Companies 14

Liver Cancer - Therapeutics under Investigation by Universities/Institutes 29

Liver Cancer - Pipeline Products Glance 32

Liver Cancer - Products under Development by Companies 35

Liver Cancer - Products under Investigation by Universities/Institutes 56

Liver Cancer - Companies Involved in Therapeutics Development 60

Liver Cancer - Therapeutics Assessment 245

Drug Profiles 277

Liver Cancer - Dormant Projects 1096

Liver Cancer - Discontinued Products 1116

Liver Cancer - Product Development Milestones 1120

Appendix 1133

List of Tables

List of Tables

Number of Products under Development for Liver Cancer, H2 2016 49

Number of Products under Development for Liver Cancer – Comparative Analysis, H2 2016 50

Number of Products under Development by Companies, H2 2016 51

Number of Products under Development by Companies, H2 2016 (Contd..1) 52

Number of Products under Development by Companies, H2 2016 (Contd..2) 53

Number of Products under Development by Companies, H2 2016 (Contd..3) 54

Number of Products under Development by Companies, H2 2016 (Contd..4) 55

Number of Products under Development by Companies, H2 2016 (Contd..5) 56

Number of Products under Development by Companies, H2 2016 (Contd..6) 57

Number of Products under Development by Companies, H2 2016 (Contd..7) 58

Number of Products under Development by Companies, H2 2016 (Contd..8) 59

Number of Products under Development by Companies, H2 2016 (Contd..9) 60

Number of Products under Development by Companies, H2 2016 (Contd..10) 61

Number of Products under Development by Companies, H2 2016 (Contd..11) 62

Number of Products under Development by Companies, H2 2016 (Contd..12) 63

Number of Products under Development by Companies, H2 2016 (Contd..13) 64

Number of Products under Development by Companies, H2 2016 (Contd..14) 65

Number of Products under Investigation by Universities/Institutes, H2 2016 66

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 67

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 68

Comparative Analysis by Late Stage Development, H2 2016 69

Comparative Analysis by Clinical Stage Development, H2 2016 70

Comparative Analysis by Early Stage Development, H2 2016 71

Products under Development by Companies, H2 2016 72

Products under Development by Companies, H2 2016 (Contd..1) 73

Products under Development by Companies, H2 2016 (Contd..2) 74

Products under Development by Companies, H2 2016 (Contd..3) 75

Products under Development by Companies, H2 2016 (Contd..4) 76

Products under Development by Companies, H2 2016 (Contd..5) 77

Products under Development by Companies, H2 2016 (Contd..6) 78

Products under Development by Companies, H2 2016 (Contd..7) 79

Products under Development by Companies, H2 2016 (Contd..8) 80

Products under Development by Companies, H2 2016 (Contd..9) 81

Products under Development by Companies, H2 2016 (Contd..10) 82

Products under Development by Companies, H2 2016 (Contd..11) 83

Products under Development by Companies, H2 2016 (Contd..12) 84

Products under Development by Companies, H2 2016 (Contd..13) 85

Products under Development by Companies, H2 2016 (Contd..14) 86

Products under Development by Companies, H2 2016 (Contd..15) 87

Products under Development by Companies, H2 2016 (Contd..16) 88

Products under Development by Companies, H2 2016 (Contd..17) 89

Products under Development by Companies, H2 2016 (Contd..18) 90

Products under Development by Companies, H2 2016 (Contd..19) 91

Products under Development by Companies, H2 2016 (Contd..20) 92

Products under Investigation by Universities/Institutes, H2 2016 93

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 94

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 95

Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 96

Liver Cancer – Pipeline by 4SC AG, H2 2016 97

Liver Cancer – Pipeline by AB Science SA, H2 2016 98

Liver Cancer – Pipeline by Acceleron Pharma Inc, H2 2016 99

Liver Cancer – Pipeline by ACROVIS Pharma AG, H2 2016 100

Liver Cancer – Pipeline by Adaptimmune Therapeutics Plc, H2 2016 101

Liver Cancer – Pipeline by Aduro BioTech Inc, H2 2016 102

Liver Cancer – Pipeline by Advenchen Laboratories LLC, H2 2016 103

Liver Cancer – Pipeline by Alfact Innovation, H2 2016 104

Liver Cancer – Pipeline by Alissa Pharma, H2 2016 105

Liver Cancer – Pipeline by Alnylam Pharmaceuticals Inc, H2 2016 106

Liver Cancer – Pipeline by American Gene Technologies International Inc, H2 2016 107

Liver Cancer – Pipeline by Amgen Inc, H2 2016 108

Liver Cancer – Pipeline by AndroScience Corp, H2 2016 109

Liver Cancer – Pipeline by APAvadis Biotechnologies Srl, H2 2016 110

Liver Cancer – Pipeline by ArQule Inc, H2 2016 111

Liver Cancer – Pipeline by Array BioPharma Inc, H2 2016 112

Liver Cancer – Pipeline by Astellas Pharma Inc, H2 2016 113

Liver Cancer – Pipeline by Astex Pharmaceuticals Inc, H2 2016 114

Liver Cancer – Pipeline by AstraZeneca Plc, H2 2016 115

Liver Cancer – Pipeline by AVEO Pharmaceuticals Inc, H2 2016 116

Liver Cancer – Pipeline by Bayer AG, H2 2016 117

Liver Cancer – Pipeline by BeiGene Ltd, H2 2016 118

Liver Cancer – Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H2 2016 119

Liver Cancer – Pipeline by Betta Pharmaceuticals Co Ltd, H2 2016 120

Liver Cancer – Pipeline by Bio-Cancer Treatment International Ltd, H2 2016 121

Liver Cancer – Pipeline by BioCancell Ltd, H2 2016 122

Liver Cancer – Pipeline by Biogazelle NV, H2 2016 123

Liver Cancer – Pipeline by Biomics Biotechnologies Co Ltd, H2 2016 124

Liver Cancer – Pipeline by Bioneer Corp, H2 2016 125

Liver Cancer – Pipeline by BioStar Pharmaceuticals Inc, H2 2016 126

Liver Cancer – Pipeline by BLR Bio LLC, H2 2016 127

Liver Cancer – Pipeline by Blueprint Medicines Corp, H2 2016 128

Liver Cancer – Pipeline by Boehringer Ingelheim GmbH, H2 2016 129

Liver Cancer – Pipeline by Boryung Pharmaceutical Co Ltd, H2 2016 130

Liver Cancer – Pipeline by Boston Biomedical Inc, H2 2016 131

Liver Cancer – Pipeline by Bristol-Myers Squibb Company, H2 2016 132

Liver Cancer – Pipeline by Can-Fite BioPharma Ltd, H2 2016 133

Liver Cancer – Pipeline by CASI Pharmaceuticals Inc, H2 2016 134

Liver Cancer – Pipeline by CBT Pharmaceuticals Inc, H2 2016 135

Liver Cancer – Pipeline by CCRP Therapeutics GmbH, H2 2016 136

Liver Cancer – Pipeline by Celgene Corp, H2 2016 137

Liver Cancer – Pipeline by Celldex Therapeutics Inc, H2 2016 138

Liver Cancer – Pipeline by Celprogen Inc, H2 2016 139

Liver Cancer – Pipeline by Celsion Corp, H2 2016 140

Liver Cancer – Pipeline by China Medical System Holdings Ltd, H2 2016 141

Liver Cancer – Pipeline by Chiome Bioscience Inc, H2 2016 142

Liver Cancer – Pipeline by Chipscreen Biosciences Ltd, H2 2016 143

Liver Cancer – Pipeline by Chroma Therapeutics Ltd, H2 2016 144

Liver Cancer – Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016 145

Liver Cancer – Pipeline by CohBar Inc, H2 2016 146

Liver Cancer – Pipeline by CZ BioMed Corp, H2 2016 147

Liver Cancer – Pipeline by Daiichi Sankyo Company Ltd, H2 2016 148

Liver Cancer – Pipeline by Delcath Systems Inc, H2 2016 149

Liver Cancer – Pipeline by Dicerna Pharmaceuticals Inc, H2 2016 150

Liver Cancer – Pipeline by Double Bond Pharmaceutical International AB, H2 2016 151

Liver Cancer – Pipeline by Eisai Co Ltd, H2 2016 152

Liver Cancer – Pipeline by Eli Lilly and Company, H2 2016 153

Liver Cancer – Pipeline by Endocyte Inc, H2 2016 154

Liver Cancer – Pipeline by Epeius Biotechnologies Corp, H2 2016 155

Liver Cancer – Pipeline by eTheRNA Immunotherapies NV, H2 2016 156

Liver Cancer – Pipeline by Eureka Therapeutics Inc, H2 2016 157

Liver Cancer – Pipeline by Exelixis Inc, H2 2016 158

Liver Cancer – Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 159

Liver Cancer – Pipeline by Faron Pharmaceuticals Oy, H2 2016 160

Liver Cancer – Pipeline by Formosa Laboratories Inc, H2 2016 161

Liver Cancer – Pipeline by Galaxy Biotech LLC, H2 2016 162

Liver Cancer – Pipeline by Genelux Corp, H2 2016 163

Liver Cancer – Pipeline by Genoscience Pharma, H2 2016 164

Liver Cancer – Pipeline by Genosco Inc, H2 2016 165

Liver Cancer – Pipeline by Gilead Sciences Inc, H2 2016 166

Liver Cancer – Pipeline by GlaxoSmithKline Plc, H2 2016 167

Liver Cancer – Pipeline by Golden Biotechnology Corp, H2 2016 168

Liver Cancer – Pipeline by Green Cross Cell Corp, H2 2016 169

Liver Cancer – Pipeline by Green Cross Corp, H2 2016 170

Liver Cancer – Pipeline by H3 Biomedicine Inc, H2 2016 171

Liver Cancer – Pipeline by HanAll Biopharma Co Ltd, H2 2016 172

Liver Cancer – Pipeline by HEC Pharm Co Ltd, H2 2016 173

Liver Cancer – Pipeline by HitGen LTD, H2 2016 174

Liver Cancer – Pipeline by Horizon Pharma Plc, H2 2016 175

Liver Cancer – Pipeline by Immune Therapeutics Inc, H2 2016 176

Liver Cancer – Pipeline by Immunicum AB, H2 2016 177

Liver Cancer – Pipeline by Immunitor Inc, H2 2016 178

Liver Cancer – Pipeline by Immunomedics Inc, H2 2016 179

Liver Cancer – Pipeline by Immunophotonics Inc, H2 2016 180

Liver Cancer – Pipeline by Immunovative Therapies Ltd, H2 2016 181

Liver Cancer – Pipeline by IMPACT Therapeutics Inc, H2 2016 182

Liver Cancer – Pipeline by In-Cell-Art SAS, H2 2016 183

Liver Cancer – Pipeline by Incanthera Ltd, H2 2016 184

Liver Cancer – Pipeline by Inovio Pharmaceuticals Inc, H2 2016 185

Liver Cancer – Pipeline by Inspyr Therapeutics Inc, H2 2016 186

Liver Cancer – Pipeline by InteRNA Technologies BV, H2 2016 187

Liver Cancer – Pipeline by Intezyne Technologies Inc, H2 2016 188

Liver Cancer – Pipeline by Jasco Pharmaceuticals LLC, H2 2016 189

Liver Cancer – Pipeline by Jenrin Discovery Inc, H2 2016 190

Liver Cancer – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2016 191

Liver Cancer – Pipeline by Johnson & Johnson, H2 2016 192

Liver Cancer – Pipeline by JW Pharmaceutical Corp, H2 2016 193

Liver Cancer – Pipeline by KAHR medical Ltd, H2 2016 194

Liver Cancer – Pipeline by Karcinolys SAS, H2 2016 195

Liver Cancer – Pipeline by Keystone Nano Inc, H2 2016 196

Liver Cancer – Pipeline by Kite Pharma Inc, H2 2016 197

Liver Cancer – Pipeline by Komipharm International Co Ltd, H2 2016 198

Liver Cancer – Pipeline by Kowa Company Ltd, H2 2016 199

Liver Cancer – Pipeline by Les Laboratoires Servier SAS, H2 2016 200

Liver Cancer – Pipeline by Lidds AB, H2 2016 201

Liver Cancer – Pipeline by Ligand Pharmaceuticals Inc, H2 2016 202

Liver Cancer – Pipeline by Lixte Biotechnology Holdings Inc, H2 2016 203

Liver Cancer – Pipeline by Lytix Biopharma AS, H2 2016 204

Liver Cancer – Pipeline by MaxCyte Inc, H2 2016 205

Liver Cancer – Pipeline by MedImmune LLC, H2 2016 206

Liver Cancer – Pipeline by Medivation Inc, H2 2016 207

Liver Cancer – Pipeline by Medivir AB, H2 2016 208

Liver Cancer – Pipeline by Merck & Co Inc, H2 2016 209

Liver Cancer – Pipeline by Merck KGaA, H2 2016 210

Liver Cancer – Pipeline by Merrimack Pharmaceuticals Inc, H2 2016 211

Liver Cancer – Pipeline by Midatech Pharma Plc, H2 2016 212

Liver Cancer – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 213

Liver Cancer – Pipeline by Mina Therapeutics Ltd, H2 2016 214

Liver Cancer – Pipeline by Molecular Partners AG, H2 2016 215

Liver Cancer – Pipeline by MultiCell Technologies Inc, H2 2016 216

Liver Cancer – Pipeline by NormOxys Inc, H2 2016 217

Liver Cancer – Pipeline by Northwest Biotherapeutics Inc, H2 2016 218

Liver Cancer – Pipeline by Novartis AG, H2 2016 219

Liver Cancer – Pipeline by NovaTarg Therapeutics Inc, H2 2016 220

Liver Cancer – Pipeline by Nymox Pharmaceutical Corp, H2 2016 221

Liver Cancer – Pipeline by Omeros Corp, H2 2016 222

Liver Cancer – Pipeline by Omnitura Therapeutics Inc, H2 2016 223

Liver Cancer – Pipeline by Oncolys BioPharma Inc, H2 2016 224

Liver Cancer – Pipeline by OncoMed Pharmaceuticals Inc, H2 2016 225

Liver Cancer – Pipeline by OncoTherapy Science Inc, H2 2016 226

Liver Cancer – Pipeline by Oneness Biotech Co Ltd, H2 2016 227

Liver Cancer – Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 228

Liver Cancer – Pipeline by Onxeo SA, H2 2016 229

Liver Cancer – Pipeline by OPKO Health Inc, H2 2016 230

Liver Cancer – Pipeline by Oribase Pharma, H2 2016 231

Liver Cancer – Pipeline by OSE Immunotherapeutics, H2 2016 232

Liver Cancer – Pipeline by Otsuka Holdings Co Ltd, H2 2016 233

Liver Cancer – Pipeline by Panacea Pharmaceuticals Inc, H2 2016 234

Liver Cancer – Pipeline by Peptinov SAS, H2 2016 235

Liver Cancer – Pipeline by PepVax Inc, H2 2016 236

Liver Cancer – Pipeline by Peregrine Pharmaceuticals Inc, H2 2016 237

Liver Cancer – Pipeline by Pfizer Inc, H2 2016 238

Liver Cancer – Pipeline by Pharma Mar SA, H2 2016 239

Liver Cancer – Pipeline by PharmAbcine Inc, H2 2016 240

Liver Cancer – Pipeline by PharmaEssentia Corp, H2 2016 241

Liver Cancer – Pipeline by Phosplatin Therapeutics LLC, H2 2016 242

Liver Cancer – Pipeline by ProMetic Life Sciences Inc, H2 2016 243

Liver Cancer – Pipeline by Provecs Medical GmbH, H2 2016 244

Liver Cancer – Pipeline by Provectus Biopharmaceuticals Inc, H2 2016 245

Liver Cancer – Pipeline by RedHill Biopharma Ltd, H2 2016 246

Liver Cancer – Pipeline by Regen BioPharma Inc, H2 2016 247

Liver Cancer – Pipeline by Regulus Therapeutics Inc, H2 2016 248

Liver Cancer – Pipeline by Rigontec GmbH, H2 2016 249

Liver Cancer – Pipeline by Samumed LLC, H2 2016 250

Liver Cancer – Pipeline by Saronic Biotechnology Inc, H2 2016 251

Liver Cancer – Pipeline by Savoy Pharmaceuticals Inc, H2 2016 252

Liver Cancer – Pipeline by Shenogen Pharma Group Ltd, H2 2016 253

Liver Cancer – Pipeline by Shenzen SiBiono GeneTech Co Ltd, H2 2016 254

Liver Cancer – Pipeline by Silence Therapeutics Plc, H2 2016 255

Liver Cancer – Pipeline by Sillajen Biotherapeutics, H2 2016 256

Liver Cancer – Pipeline by Simcere Pharmaceutical Group, H2 2016 257

Liver Cancer – Pipeline by Somantix BV, H2 2016 258

Liver Cancer – Pipeline by Sorrento Therapeutics Inc, H2 2016 259

Liver Cancer – Pipeline by Synovo GmbH, H2 2016 260

Liver Cancer – Pipeline by TaiRx Inc, H2 2016 261

Liver Cancer – Pipeline by Taiwan Liposome Company Ltd, H2 2016 262

Liver Cancer – Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016 263

Liver Cancer – Pipeline by Targetome SA, H2 2016 264

Liver Cancer – Pipeline by TC BioPharm Ltd, H2 2016 265

Liver Cancer – Pipeline by Tessa Therapeutics Pte Ltd, H2 2016 266

Liver Cancer – Pipeline by Therapure Biopharma Inc, H2 2016 267

Liver Cancer – Pipeline by Theravectys SA, H2 2016 268

Liver Cancer – Pipeline by Threshold Pharmaceuticals Inc, H2 2016 269

Liver Cancer – Pipeline by Tiziana Life Sciences Plc, H2 2016 270

Liver Cancer – Pipeline by TRACON Pharmaceuticals Inc, H2 2016 271

Liver Cancer – Pipeline by Transgene Biotek Ltd, H2 2016 272

Liver Cancer – Pipeline by Tumorend LLC, H2 2016 273

Liver Cancer – Pipeline by UbiVac LLC, H2 2016 274

Liver Cancer – Pipeline by VasGene Therapeutics Inc, H2 2016 275

Liver Cancer – Pipeline by Vaxon Biotech, H2 2016 276

Liver Cancer – Pipeline by Vect-Horus SAS, H2 2016 277

Liver Cancer – Pipeline by Verlyx Pharma Inc, H2 2016 278

Liver Cancer – Pipeline by VG Life Sciences Inc, H2 2016 279

Liver Cancer – Pipeline by Vicus Therapeutics LLC, H2 2016 280

Liver Cancer – Pipeline by Virttu Biologics Ltd, H2 2016 281

Assessment by Monotherapy Products, H2 2016 282

Assessment by Combination Products, H2 2016 283

Number of Products by Stage and Target, H2 2016 285

Number of Products by Stage and Mechanism of Action, H2 2016 298

Number of Products by Stage and Route of Administration, H2 2016 311

Number of Products by Stage and Molecule Type, H2 2016 313

Liver Cancer – Dormant Projects, H2 2016 1133

Liver Cancer – Dormant Projects (Contd..1), H2 2016 1134

Liver Cancer – Dormant Projects (Contd..2), H2 2016 1135

Liver Cancer – Dormant Projects (Contd..3), H2 2016 1136

Liver Cancer – Dormant Projects (Contd..4), H2 2016 1137

Liver Cancer – Dormant Projects (Contd..5), H2 2016 1138

Liver Cancer – Dormant Projects (Contd..6), H2 2016 1139

Liver Cancer – Dormant Projects (Contd..7), H2 2016 1140

Liver Cancer – Dormant Projects (Contd..8), H2 2016 1141

Liver Cancer – Dormant Projects (Contd..9), H2 2016 1142

Liver Cancer – Dormant Projects (Contd..10), H2 2016 1143

Liver Cancer – Dormant Projects (Contd..11), H2 2016 1144

Liver Cancer – Dormant Projects (Contd..12), H2 2016 1145

Liver Cancer – Dormant Projects (Contd..13), H2 2016 1146

Liver Cancer – Dormant Projects (Contd..14), H2 2016 1147

Liver Cancer – Dormant Projects (Contd..15), H2 2016 1148

Liver Cancer – Dormant Projects (Contd..16), H2 2016 1149

Liver Cancer – Dormant Projects (Contd..17), H2 2016 1150

Liver Cancer – Dormant Projects (Contd..18), H2 2016 1151

Liver Cancer – Dormant Projects (Contd..19), H2 2016 1152

Liver Cancer – Discontinued Products, H2 2016 1153

Liver Cancer – Discontinued Products (Contd..1), H2 2016 1154

Liver Cancer – Discontinued Products (Contd..2), H2 2016 1155

Liver Cancer – Discontinued Products (Contd..3), H2 2016 1156

List of Figures

List of Figures

Number of Products under Development for Liver Cancer, H2 2016 49

Number of Products under Development for Liver Cancer – Comparative Analysis, H2 2016 50

Number of Products under Development by Companies, H2 2016 51

Number of Products under Investigation by Universities/Institutes, H2 2016 66

Comparative Analysis by Late Stage Development, H2 2016 69

Comparative Analysis by Clinical Stage Development, H2 2016 70

Comparative Analysis by Early Stage Products, H2 2016 71

Assessment by Monotherapy Products, H2 2016 282

Assessment by Combination Products, H2 2016 283

Number of Products by Top 10 Targets, H2 2016 284

Number of Products by Stage and Top 10 Targets, H2 2016 284

Number of Products by Top 10 Mechanism of Actions, H2 2016 297

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 297

Number of Products by Top 10 Routes of Administration, H2 2016 310

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 310

Number of Products by Top 10 Molecule Types, H2 2016 312

Number of Products by Stage and Top 10 Molecule Types, H2 2016 312

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports